Please login to the form below

Not currently logged in
Email:
Password:

gilteritinib

This page shows the latest gilteritinib news and features for those working in and with pharma, biotech and healthcare.

Astellas, Catalyst approvals set up record year for FDA approvals

Astellas, Catalyst approvals set up record year for FDA approvals

The approvals of Astellas’ FLT3 inhibitor Xospata (gilteritinib) for acute myeloid leukaemia and Catalyst Pharmaceuticals’ Firdapse (amifampridine) for rare autoimmune disease Lambert-Eaton Myasthenic Syndrome (LEMS), already put the number for

Latest news

  • FDA fast-tracks Astellas' Rydapt rival FDA fast-tracks Astellas' Rydapt rival

    Astellas Pharma has claimed a fast-track designation in the US for its FLT3 inhibitor gilteritinib, a drug that could rival Novartis’ budding $250m-plus product Rydapt (midostaurin). ... The FDA gave the status to gilteritinib as a treatment for adults

  • Astellas extends phase III programme for Rydapt rival gilteritinib Astellas extends phase III programme for Rydapt rival gilteritinib

    Astellas has started a fourth phase III trial of acute myeloid leukaemia (AML) drug gilteritinib, a FLT3 inhibitor racing to join Novartis' recently-approved Rydapt on the market. ... Given this reality, it is exciting to study gilteritinib in patients

  • Novartis' Rydapt approval ends long AML therapy drought Novartis' Rydapt approval ends long AML therapy drought

    Meanwhile Astellas' gilteritinib - billed as a second-generation FLT3 inhibitor that avoids a resistance mechanism seen with earlier drugs - is also in late-stage testing.

More from news
Approximately 2 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Novasecta

We are a specialist strategy consulting firm for pharmaceutical and biotech companies. We help our clients to achieve significant performance...

Latest intelligence

London
“Brexit has been a catalyst for UK clinical research... it’s turbocharged change”
The UK clinical trials environment has been transformed in recent years – but can it really buck Brexit’s risks and uncertainties?...
The Future of Pharma sales: fast forward to 2029
Change is inevitable, and necessary, for growth in business....
International Women's Day - 8 March 2019
International Women's Day has been celebrated since its inception in 1911. But how far have we come?...

Infographics